JP2024543942A5 - - Google Patents
Info
- Publication number
- JP2024543942A5 JP2024543942A5 JP2024532180A JP2024532180A JP2024543942A5 JP 2024543942 A5 JP2024543942 A5 JP 2024543942A5 JP 2024532180 A JP2024532180 A JP 2024532180A JP 2024532180 A JP2024532180 A JP 2024532180A JP 2024543942 A5 JP2024543942 A5 JP 2024543942A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- contains sequence
- fusion protein
- seq
- cdr1l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284937P | 2021-12-01 | 2021-12-01 | |
| US63/284,937 | 2021-12-01 | ||
| PCT/US2022/080542 WO2023102367A1 (en) | 2021-12-01 | 2022-11-29 | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543942A JP2024543942A (ja) | 2024-11-26 |
| JP2024543942A5 true JP2024543942A5 (https=) | 2025-12-08 |
Family
ID=84519919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532180A Pending JP2024543942A (ja) | 2021-12-01 | 2022-11-29 | Ｂ７－ｈ４抗体及び抗ｂ７－ｈ４抗体／ｉｌ－１５融合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230312724A1 (https=) |
| EP (1) | EP4441093A1 (https=) |
| JP (1) | JP2024543942A (https=) |
| KR (1) | KR20240112342A (https=) |
| CN (1) | CN118339184A (https=) |
| AR (1) | AR127806A1 (https=) |
| AU (1) | AU2022402985A1 (https=) |
| CA (1) | CA3238965A1 (https=) |
| CO (1) | CO2024008181A2 (https=) |
| IL (1) | IL313159A (https=) |
| MX (1) | MX2024006573A (https=) |
| TW (1) | TW202346320A (https=) |
| WO (1) | WO2023102367A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US9422351B2 (en) * | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| PL3094351T3 (pl) * | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
| WO2016040724A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| EP3728705A4 (en) * | 2017-12-18 | 2022-01-19 | Charles River Laboratories, Inc. | RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY |
| CN116693686A (zh) * | 2018-02-11 | 2023-09-05 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| AU2019228381B2 (en) * | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
-
2022
- 2022-11-29 CA CA3238965A patent/CA3238965A1/en active Pending
- 2022-11-29 AU AU2022402985A patent/AU2022402985A1/en active Pending
- 2022-11-29 MX MX2024006573A patent/MX2024006573A/es unknown
- 2022-11-29 IL IL313159A patent/IL313159A/en unknown
- 2022-11-29 KR KR1020247021496A patent/KR20240112342A/ko active Pending
- 2022-11-29 TW TW111145737A patent/TW202346320A/zh unknown
- 2022-11-29 US US18/059,548 patent/US20230312724A1/en active Pending
- 2022-11-29 AR ARP220103274A patent/AR127806A1/es unknown
- 2022-11-29 WO PCT/US2022/080542 patent/WO2023102367A1/en not_active Ceased
- 2022-11-29 EP EP22823298.9A patent/EP4441093A1/en active Pending
- 2022-11-29 JP JP2024532180A patent/JP2024543942A/ja active Pending
- 2022-11-29 CN CN202280079188.6A patent/CN118339184A/zh active Pending
-
2024
- 2024-06-24 CO CONC2024/0008181A patent/CO2024008181A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023085476A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| JP2022551969A5 (https=) | ||
| HRP20250443T1 (hr) | Proteini koji vežu dll3/cd3 za liječenje raka | |
| RU2019134338A (ru) | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 | |
| RU2019110752A (ru) | Антитела к вирусу денге, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| JP2021533779A5 (https=) | ||
| RU2007129676A (ru) | Антитела к рецептору альфа 1 il-13 и их применение | |
| HRP20211528T1 (hr) | Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2019533441A5 (https=) | ||
| JP2017537896A5 (https=) | ||
| HRP20200306T1 (hr) | Bispecifične molekule vezane na antigene koji aktiviraju t stanice specifične za cd3 i cea | |
| JP2019502712A5 (https=) | ||
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| JP2021534220A5 (https=) | ||
| JP2021535758A5 (https=) | ||
| JP2021507698A5 (https=) | ||
| JP2017534646A5 (https=) | ||
| JP2021094022A5 (https=) | ||
| JP2022505445A5 (https=) | ||
| JP2024501403A5 (https=) | ||
| JP2024537779A5 (https=) | ||
| JP2021521781A5 (https=) | ||
| JPWO2022102768A5 (https=) |